BIOMARIN PHARMACEUTICAL INC Earnings Per Share (Basic)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Earnings Per Share (Basic) of $0.23 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for the quarter ending 2026-06-30 was $0.23, a 81.60% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for the quarter ending 2026-03-31 was $0.55, a 43.30% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for the quarter ending 2025-12-31 was -$0.24, a 136.98% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.16, a 128.57% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for fiscal 2025 was $1.82, a 19.11% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for fiscal 2024 was $2.25, a 152.81% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for fiscal 2023 was $0.89, a 17.11% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC earnings per share, basic for fiscal 2022 was $0.76.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.23 10-Q · filed 2026-08-06 | $0.78 10-Q · filed 2026-08-06 | $0.54 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.38 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2026-03-31 | $0.55 10-Q · filed 2026-05-05 | $0.31 derived: net income ÷ weighted average shares · filed 2026-05-05 | $0.15 derived: net income ÷ weighted average shares · filed 2026-05-05 | $1.40 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-12-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.85 derived: net income ÷ weighted average shares · filed 2026-08-06 | $1.82 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$0.16 10-Q · filed 2025-10-28 | $1.09 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.06 10-Q · filed 2025-10-28 | $2.72 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-06-30 | $1.25 10-Q · filed 2026-08-06 | $2.23 10-Q · filed 2026-08-06 | $2.88 derived: net income ÷ weighted average shares · filed 2026-08-06 | $3.44 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-03-31 | $0.97 10-Q · filed 2026-05-05 | $1.63 derived: net income ÷ weighted average shares · filed 2026-05-05 | $2.19 derived: net income ÷ weighted average shares · filed 2026-05-05 | $2.75 derived: net income ÷ weighted average shares · filed 2026-05-05 | |||
| 2024-12-31 | $0.66 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.21 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.78 derived: net income ÷ weighted average shares · filed 2026-02-26 | $2.25 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.56 10-Q · filed 2025-10-28 | $1.12 derived: net income ÷ weighted average shares · filed 2025-10-28 | $1.59 10-Q · filed 2025-10-28 | $1.70 derived: net income ÷ weighted average shares · filed 2026-02-26 | |||
| 2024-06-30 | $0.56 10-Q · filed 2025-08-05 | $1.03 10-Q · filed 2025-08-05 | $1.14 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.36 derived: net income ÷ weighted average shares · filed 2026-02-26 | |||
| 2024-03-31 | $0.47 10-Q · filed 2025-05-02 | $0.58 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.79 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.09 derived: net income ÷ weighted average shares · filed 2026-02-26 | |||
| 2023-12-31 | $0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.32 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.62 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.89 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $0.21 10-Q · filed 2024-10-31 | $0.51 derived: net income ÷ weighted average shares · filed 2024-10-31 | $0.78 10-Q · filed 2024-10-31 | $0.79 derived: net income ÷ weighted average shares · filed 2025-02-24 | |||
| 2023-06-30 | $0.30 10-Q · filed 2024-08-05 | $0.57 10-Q · filed 2024-08-05 | $0.57 derived: net income ÷ weighted average shares · filed 2025-02-24 | $0.54 derived: net income ÷ weighted average shares · filed 2025-02-24 | |||
| 2023-03-31 | $0.27 10-Q · filed 2024-04-26 | $0.27 derived: net income ÷ weighted average shares · filed 2025-02-24 | $0.24 derived: net income ÷ weighted average shares · filed 2025-02-24 | $0.39 derived: net income ÷ weighted average shares · filed 2025-02-24 | |||
| 2022-12-31 | -$0.00 derived: net income ÷ weighted average shares · filed 2025-02-24 | -$0.04 derived: net income ÷ weighted average shares · filed 2025-02-24 | $0.11 derived: net income ÷ weighted average shares · filed 2025-02-24 | $0.76 10-K · filed 2025-02-24 | |||
| 2022-09-30 | -$0.04 10-Q · filed 2023-11-02 | $0.11 derived: net income ÷ weighted average shares · filed 2023-11-02 | $0.77 10-Q · filed 2023-11-02 | $0.45 derived: net income ÷ weighted average shares · filed 2024-02-26 | |||
| 2022-06-30 | $0.15 10-Q · filed 2023-08-02 | $0.80 10-Q · filed 2023-08-02 | $0.49 derived: net income ÷ weighted average shares · filed 2024-02-26 | $0.29 derived: net income ÷ weighted average shares · filed 2024-02-26 | |||
| 2022-03-31 | $0.66 10-Q · filed 2023-04-28 | $0.34 derived: net income ÷ weighted average shares · filed 2024-02-26 | $0.14 derived: net income ÷ weighted average shares · filed 2024-02-26 | $0.21 derived: net income ÷ weighted average shares · filed 2024-02-26 | |||
| 2021-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$0.44 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$0.35 10-K · filed 2024-02-26 | |||
| 2021-09-30 | -$0.20 10-Q · filed 2022-10-28 | -$0.13 derived: net income ÷ weighted average shares · filed 2022-10-28 | -$0.03 10-Q · filed 2022-10-28 | $0.06 derived: net income ÷ weighted average shares · filed 2023-02-27 | |||
| 2021-06-30 | $0.07 10-Q · filed 2022-08-04 | $0.17 10-Q · filed 2022-08-04 | $0.26 derived: net income ÷ weighted average shares · filed 2023-02-27 | $4.58 derived: net income ÷ weighted average shares · filed 2023-02-27 | |||
| 2021-03-31 | $0.10 10-Q · filed 2022-04-29 | $0.19 derived: net income ÷ weighted average shares · filed 2023-02-27 | $4.51 derived: net income ÷ weighted average shares · filed 2023-02-27 | ||||
| 2020-12-31 | $0.09 derived: net income ÷ weighted average shares · filed 2023-02-27 | $4.42 derived: net income ÷ weighted average shares · filed 2023-02-27 | $4.72 10-K · filed 2023-02-27 | $4.75 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $4.33 10-Q · filed 2021-10-29 | $4.63 10-Q · filed 2021-10-29 | |||||
| 2020-06-30 | -$0.16 10-Q · filed 2021-07-30 | $0.29 10-Q · filed 2021-07-30 | |||||
| 2020-03-31 | $0.45 10-Q · filed 2021-04-30 | $0.54 derived: net income ÷ weighted average shares · filed 2022-02-25 | $0.84 derived: net income ÷ weighted average shares · filed 2022-02-25 | ||||
| 2019-12-31 | $0.08 derived: net income ÷ weighted average shares · filed 2022-02-25 | $0.39 derived: net income ÷ weighted average shares · filed 2022-02-25 | -$0.13 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $0.31 10-Q · filed 2020-11-06 | -$0.22 10-Q · filed 2020-11-06 | |||||
| 2019-06-30 | -$0.21 10-Q · filed 2020-08-05 | -$0.53 10-Q · filed 2020-08-05 | |||||
| 2019-03-31 | -$0.32 10-Q · filed 2020-05-01 | -$0.34 derived: net income ÷ weighted average shares · filed 2021-02-26 | -$0.41 derived: net income ÷ weighted average shares · filed 2021-02-26 | ||||
| 2018-12-31 | -$0.02 derived: net income ÷ weighted average shares · filed 2021-02-26 | -$0.09 derived: net income ÷ weighted average shares · filed 2021-02-26 | -$0.44 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$0.07 10-Q/A · filed 2019-11-04 | -$0.42 10-Q/A · filed 2019-11-04 | |||||
| 2018-03-31 | -$0.25 10-Q · filed 2019-04-29 | -$0.54 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$0.62 derived: net income ÷ weighted average shares · filed 2020-02-27 | ||||
| 2017-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$0.36 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$0.67 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | -$0.07 10-Q · filed 2017-10-31 | -$0.38 10-Q · filed 2017-10-31 | |||||
| 2017-03-31 | -$0.09 10-Q · filed 2018-04-27 | -$0.62 derived: net income ÷ weighted average shares · filed 2019-02-28 | -$0.85 derived: net income ÷ weighted average shares · filed 2019-02-28 | ||||
| 2016-12-31 | -$0.53 derived: net income ÷ weighted average shares · filed 2019-02-28 | -$0.75 derived: net income ÷ weighted average shares · filed 2019-02-28 | -$3.80 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$0.22 10-Q · filed 2017-10-31 | -$0.26 10-Q · filed 2016-11-03 | -$3.29 10-Q · filed 2017-10-31 | -$3.36 10-Q · filed 2016-11-03 | |||
| 2015-12-31 | $0.43 derived: net income ÷ weighted average shares · filed 2018-02-26 | -$0.14 derived: net income ÷ weighted average shares · filed 2018-02-26 | -$0.65 derived: net income ÷ weighted average shares · filed 2018-02-26 | -$1.07 10-K · filed 2018-02-26 | |||
| 2015-09-30 | -$0.57 10-Q · filed 2016-11-03 | -$1.08 derived: net income ÷ weighted average shares · filed 2016-11-03 | -$1.51 10-Q · filed 2016-11-03 | -$1.98 derived: net income ÷ weighted average shares · filed 2017-02-27 | |||
| 2015-06-30 | -$0.51 10-Q · filed 2015-08-05 | -$0.94 10-Q · filed 2015-08-05 | -$1.41 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$1.38 derived: net income ÷ weighted average shares · filed 2017-02-27 | |||
| 2015-03-31 | -$0.43 10-Q · filed 2015-05-05 | -$0.90 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$0.86 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$1.09 derived: net income ÷ weighted average shares · filed 2017-02-27 | |||
| 2014-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$0.42 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$0.65 derived: net income ÷ weighted average shares · filed 2017-02-27 | -$0.92 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $0.05 10-Q · filed 2015-11-02 | -$0.18 derived: net income ÷ weighted average shares · filed 2015-11-02 | -$0.44 10-Q · filed 2015-11-02 | ||||
| 2014-06-30 | -$0.23 10-Q · filed 2015-08-05 | -$0.49 10-Q · filed 2015-08-05 | |||||
| 2014-03-31 | -$0.26 10-Q · filed 2015-05-05 | ||||||
| 2013-09-30 | -$0.38 10-Q · filed 2014-10-28 | -$0.53 derived: net income ÷ weighted average shares · filed 2014-10-28 | -$0.84 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | -$0.15 10-Q · filed 2014-07-31 | -$0.46 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | -$0.31 10-Q · filed 2014-05-02 | ||||||
| 2012-12-31 | -$0.95 10-K · filed 2013-02-26 | ||||||
| 2012-06-30 | -$0.27 10-Q · filed 2013-07-29 | -$0.48 10-Q · filed 2013-07-29 | -$0.71 derived: net income ÷ weighted average shares · filed 2013-07-29 | -$0.87 derived: net income ÷ weighted average shares · filed 2013-07-29 | |||
| 2012-03-31 | -$0.21 10-Q · filed 2012-04-30 | -$0.44 derived: net income ÷ weighted average shares · filed 2013-02-26 | -$0.60 derived: net income ÷ weighted average shares · filed 2013-02-26 | -$0.65 derived: net income ÷ weighted average shares · filed 2013-02-26 | |||
| 2011-12-31 | -$0.23 derived: net income ÷ weighted average shares · filed 2013-02-26 | -$0.39 derived: net income ÷ weighted average shares · filed 2013-02-26 | -$0.44 derived: net income ÷ weighted average shares · filed 2013-02-26 | -$0.48 10-K · filed 2013-02-26 | |||
| 2011-09-30 | -$0.16 10-Q · filed 2011-10-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2011-10-31 | -$0.24 10-Q · filed 2011-10-31 | -$0.36 derived: net income ÷ weighted average shares · filed 2013-02-26 | |||
| 2011-06-30 | -$0.05 10-Q · filed 2011-08-01 | -$0.09 10-Q · filed 2011-08-01 | -$0.20 derived: net income ÷ weighted average shares · filed 2013-02-26 | $1.82 derived: net income ÷ weighted average shares · filed 2013-02-26 | |||
| 2011-03-31 | -$0.04 10-Q · filed 2012-04-30 | -$0.15 derived: net income ÷ weighted average shares · filed 2013-02-26 | $1.88 derived: net income ÷ weighted average shares · filed 2013-02-26 | $1.90 derived: net income ÷ weighted average shares · filed 2013-02-26 | |||
| 2010-12-31 | -$0.11 derived: net income ÷ weighted average shares · filed 2013-02-26 | $1.96 derived: net income ÷ weighted average shares · filed 2013-02-26 | $1.97 derived: net income ÷ weighted average shares · filed 2013-02-26 | $2.00 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $2.13 10-Q · filed 2011-10-31 | $2.13 derived: net income ÷ weighted average shares · filed 2011-10-31 | $2.14 10-Q · filed 2011-10-31 | ||||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-01 | $0.01 10-Q · filed 2011-08-01 | |||||
| 2009-12-31 | $0.00 10-K · filed 2012-02-22 | ||||||
| 2009-09-30 | $0.07 10-Q · filed 2010-10-29 | -$0.05 10-Q · filed 2010-10-29 | |||||
| 2009-06-30 | $0.01 10-Q · filed 2010-08-04 | -$0.12 10-Q · filed 2010-08-04 | |||||
| 2008-12-31 | $0.31 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |